Five things for pharma marketers to know: Tuesday, June 27, 2017

Share this content:

1. Merck said its experimental CETP inhibitor anacetrapib reduced heart problems and strokes in a five-year clinical trial of 30,000 patients. Pfizer, Eli Lilly, and Roche had developed drugs in the same class, but they failed in clinical trials. (Forbes)

2.Purdue Pharma lawyers argued that “the public has no right of access” to certain marketing materials related to its prescription opioid OxyContin, during a court hearing in response to a motion filed by Stat. (Stat)

3. Roche's experimental haemophilia treatment emicizumab reduced the bleed rate by 87% in a Phase-III study, the drugmaker said. (PharmaTimes)

4. Blood cancer patients on a combination therapy testing Seattle Genetics and Takeda Pharmaceuticals' lymphoma treatment Adcetris had a survival rate of 82%, compared to 77% in the control arm, in a Phase-III study. (Endpoints News)

5. Patients taking Alder BioPharmaceuticals' experimental migraine drug eptinezumab saw a reduction in monthly migraine days in a Phase-III study, but the results were below investor's expectations. (Reuters)

Share this content:
Scroll down to see the next article